Trump Announces Phased Tariffs to Reshore Generic Drug Production

President Donald Trump announced a phased tariff regime for generic medicines imported into the United States, designed to force pharmaceutical companies to reshore production. According to the plan, generic drugs will remain at a 0% tariff starting August 1, 2026, for two years. In August 2028, a 100% duty will be imposed, rising to 200% in August 2029 for companies that fail to establish domestic manufacturing facilities.

The policy primarily targets exporters in India, China, and Europe. India is expected to be the most impacted, as it currently supplies 47% of all generic prescriptions in the U.S. Following the announcement, the Nifty Pharma index declined, and shares of major Indian firms including Sun Pharma and Dr. Reddy's Laboratories dropped. The European Commission argues that EU generic medicines should be exempt based on a 2025 transatlantic trade deal.

Industry reactions have been critical. The Indian Pharmaceutical Alliance stated that tariffs alone will not create a sustainable manufacturing base and warned that the two-year window is too short for FDA regulatory approval. Basel-based Sandoz noted it is too early to assess the impact, even as it plans to close its only U.S. site in New York by late 2026. Analysts warn the move could lead to drug shortages and higher consumer prices by removing the cost advantages of foreign producers.